Skip to content
PubMed This is a summary of 44 peer-reviewed journal articles Updated
Nephrology

Fanconi renotubular syndrome 4 with HNF4A-MODY: A Patient Guide

At a Glance

FRTS4 with HNF4A-MODY is a rare HNF4A-related condition that can shift from newborn low blood sugar to childhood kidney and bone problems and later diabetes. Kidney, hormone, and genetics specialists coordinate monitoring as symptoms change.

Fanconi Renotubular Syndrome 4 with Maturity-Onset Diabetes of the Young (FRTS4 with MODY1) is an exceptionally rare genetic condition that affects the body’s internal “sorting” and “fuel” systems. At its core, this condition is caused by a change in the HNF4A gene, which serves as a master instruction manual for the development of cells in the kidneys and the pancreas [1]. Because this single gene helps manage how the kidneys recycle nutrients and how the pancreas releases insulin, a variation in its code can lead to a sequence of different health challenges that emerge at different stages of life.

What is Known and What Remains Uncertain

Because this condition is so rare, much of the medical evidence about FRTS4 comes from a single international study of just 25 patients, most of whom carried one specific genetic variant (p.Arg85Trp) [1]. While that study identified a common sequence of symptoms, not every person with an HNF4A variant will experience every phase, and the severity of kidney and pancreas issues can vary widely from person to person.

The condition is often described as “multi-phasic” because its symptoms change as a person grows. In the earliest phase, some infants are born with a high birth weight and experience dangerously low blood sugar, known as hyperinsulinemic hypoglycemia, because their pancreas produces too much insulin [2]. As this newborn phase resolves, the focus typically shifts to the kidneys in early childhood. During this second phase, the kidneys develop Fanconi syndrome, where they fail to reclaim vital minerals, sugar, and proteins from the urine. This “leaking” can lead to softened bones (rickets) and a gradual, progressive decline in overall kidney function over many years [1].

As patients reach adolescence or early adulthood, the pancreas often enters a third phase where it begins to produce too little insulin, rather than too much. This leads to a specific form of diabetes known as HNF4A-MODY (MODY1) [3]. Unlike more common forms of diabetes, MODY1 is typically not an autoimmune disease; instead, it is a direct result of the pancreatic cells struggling to release insulin correctly. Understanding this progression is vital because the treatments used for this specific type of diabetes often differ from those used for more common types, frequently responding well to specific oral medications [4].

Living with this condition requires a proactive, “whole-body” approach to medical care. Because the kidneys and pancreas are so closely linked by this genetic change, the most effective care happens when kidney specialists (nephrologists) and hormone specialists (endocrinologists) work together to monitor bone health, kidney filtration, and blood sugar levels. While the rarity of the diagnosis can feel isolating, understanding the underlying genetic cause empowers families to stay ahead of each phase, ensuring that growth, bone strength, and metabolic health are supported throughout a lifetime [5].

Common questions in this guide

What causes Fanconi renotubular syndrome 4 with HNF4A-MODY?
The condition is caused by a change in the HNF4A gene, which helps regulate kidney nutrient recycling and insulin release from the pancreas. Different HNF4A variants can produce different symptoms, so not everyone experiences the same phases or severity.
What health problems can appear at different ages with FRTS4?
Some infants have high birth weight and low blood sugar because the pancreas makes too much insulin. In childhood, Fanconi syndrome can cause minerals, glucose, and proteins to be lost in urine, leading to rickets and declining kidney function; later, reduced insulin release can cause HNF4A-MODY.
How is HNF4A-MODY different from more common types of diabetes?
HNF4A-MODY is typically not an autoimmune disease; it results from pancreatic cells having difficulty releasing insulin. Its treatment can differ from treatment for common diabetes, and it may respond well to specific oral medications.
Which specialists should care for someone with FRTS4?
Care commonly involves a nephrologist for kidney and mineral issues, an endocrinologist for blood sugar and insulin-related concerns, and a genetics professional for variant interpretation and family counseling. Coordinating these specialists can help the care team recognize changes over time.
What should be monitored over time with FRTS4 and HNF4A-MODY?
Care teams may monitor kidney filtration, urine losses, bone health, growth, and blood sugar. Monitoring helps clinicians identify changes as the condition moves from early low blood sugar to kidney problems or later diabetes, although not every person follows the same pattern.
Does the p.Arg85Trp variant confirm the diagnosis?
The p.Arg85Trp variant was found in most patients in the small international study described, but the findings do not mean every person with an HNF4A variant has the same condition or symptoms. A genetics professional should interpret an individual result together with the person's clinical features and family history.

Get notified when new evidence is published on Fanconi renotubular syndrome 4 with maturity-onset diabetes of the young.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (5)
  1. 1

    Phenotypic Spectrum of HNF4α-Associated Fanconi Renotubular Syndrome.

    Emma F, Böckenhauer D, Mallett AJ, et al.

    Kidney international reports 2026; (11(8)):106616 doi:10.1016/j.ekir.2026.106616.

    PMID: 42440446
  2. 2

    A Novel HNF4A Mutation Causing Three Phenotypic Forms of Glucose Dysregulation in a Family.

    Chandran S, Rajadurai VS, Hoi WH, et al.

    Frontiers in pediatrics 2020; (8()):320 doi:10.3389/fped.2020.00320.

    PMID: 32670997
  3. 3

    Heterozygous recurrent HNF4A variant p.Arg85Trp causes Fanconi renotubular syndrome 4 with maturity onset diabetes of the young, an autosomal dominant phenocopy of Fanconi Bickel syndrome with colobomas.

    Sheppard SE, Barrett B, Muraresku C, et al.

    American journal of medical genetics. Part A 2021; (185(2)):566-570 doi:10.1002/ajmg.a.61978.

    PMID: 33251707
  4. 4

    Case Report: Beyond type 1 diabetes: a case of delayed MODY1 diagnosis and successful transition to sulfonylurea therapy.

    Gulisano C, Aloi C, Salina A, et al.

    Frontiers in medicine 2025; (12()):1590935 doi:10.3389/fmed.2025.1590935.

    PMID: 40486195
  5. 5

    Maturity Onset Diabetes of the Young (MODY): French National Diagnosis and Care Protocol (PNDS, Protocole National de Diagnostic et de Soins).

    Dubois-Laforgue D, Donadille B, Ciangura C, et al.

    Orphanet journal of rare diseases 2026; (17(Suppl 1)).

    PMID: 42227416

This page is for informational purposes only and does not constitute medical advice about FRTS4 with HNF4A-MODY. Your nephrologist, endocrinologist, and genetics professional can help interpret your results and plan care.